CD33 and neoplasm: NSG-SGM3 mice (male, 9–13 weeks old) received 0.5 × 106 OCI-AML2 cells (GFP+, Luciferase (Luc)+) intravenously followed by a single administration of 1 × 107 CD33-CAR-NK cells at day 3 post tumor cell injection.